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Abstract
Objective
Endoscopic lung volume reduction (ELVR) with valves has been shown to improve COPD
patients with severe emphysema. However, a major complication is pneumothoraces,
occurring typically soon after valve implantation, with severe consequences if not man-
aged promptly. Based on the knowledge that strain activity is related to a higher risk of
pneumothoraces, we asked whether modifying post-operative medical care with the inclu-
sion of strict short-term limitation of strain activity is associated with a lower incidence
of pneumothorax.
Methods
Seventy-two (72) emphysematous patients without collateral ventilation were treated with
bronchial valves and included in the study. Thirty-two (32) patients received standard post-
implantation medical management (Standard Medical Care (SMC)), and 40 patients re-
ceived a modified medical care that included an additional bed rest for 48 hours and cough
suppression, as needed (Modified Medical Care (MMC)).
Results
The baseline characteristics were similar for the two groups, except there were more males
in the SMC cohort. Overall, ten pneumothoraces occurred up to four days after ELVR, eight
pneumothoraces in the SMC, and only two in the MMC cohorts (p=0.02). Complicated
pneumothoraces and pneumothoraces after upper lobe treatment were significantly lower
in MMC (p=0.02). Major clinical outcomes showed no significant differences between the
two cohorts.
PLOS ONE | DOI:10.1371/journal.pone.0128097 May 26, 2015 1 / 14
OPEN ACCESS
Citation: Herzog D, Poellinger A, Doellinger F,
Schuermann D, Temmesfeld-Wollbrueck B, Froeling
V, et al. (2015) Modifying Post-Operative Medical
Care after EBV Implant May Reduce Pneumothorax
Incidence. PLoS ONE 10(5): e0128097. doi:10.1371/
journal.pone.0128097
Academic Editor: Stefan Worgall, Weill Medical
College of Cornell University, UNITED STATES
Received: September 2, 2014
Accepted: April 23, 2015
Published: May 26, 2015
Copyright: © 2015 Herzog et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are
credited.
Data Availability Statement: All relevant data are
within the paper.
Funding: The authors received no specific funding
for this work.
Competing Interests: I have read the journal’s policy
and the authors of this manuscript have the following
competing interests: Ralf-Harto Huebner has
received lecture fees for educational activities from
Pulmonx. This does not alter the authors’ adherence
to PLOS ONE policies on sharing data and materials.
s
o
u
r
c
e
:
 
ht
tp
s:
//
do
i.
or
g/
10
.7
89
2/
bo
ri
s.
77
17
5 
| 
do
wn
lo
ad
ed
: 
23
.2
.2
01
6
Conclusions
In conclusion, modifying post-operative medical care to include bed rest for 48 hours after
ELVR and cough suppression, if needed, might reduce the incidence of pneumothoraces.
Prospective randomized studies with larger numbers of well-matched patients are needed
to confirm the data.
Introduction
COPD, characterized by hyperinflation of the lung resulting in reduced gas exchange, is a
major cause of morbidity and mortality worldwide. Endoscopic lung volume reduction
(ELVR) with valves has been shown to improve lung function, quality of life and exercise ca-
pacity in severe COPD patients [1–9]. Pneumothoraces after ELVR are directly related to valve
implantation [10] and result from the rapid shifts in volume between lung lobes. While the tar-
get lobe quickly loses volume following valve implantation, the adjacent ipsilateral untreated
lobe expands to occupy the newly created space in the chest cavity. This volume shift can occur
very quickly resulting in a parenchymal rupture of the untreated ipsilateral lobe [11]. The prev-
alence of pneumothorax after ELVR has recently increased due to stricter selection criteria of
patients for valve therapy [12]. An absence of collateral ventilation [13], a heterogeneous em-
physema [14] and a total occlusion of the target lobe have been shown to be predictive factors
of better clinical outcome but also higher rates of pneumothoraces [15]. Although pneumotho-
rax is a complication following ELVR, it seems not to have any negative impact on clinical out-
comes [10].
There are also reports of correlations between strain activity, Valsalva maneuvers and the
occurrence of pneumothoraces [16]. Nevertheless, data are still inconsistent and may not rep-
resent secondary pneumothoraces such as those following ELVR [17]. Interestingly, a recent
paper identified biomechanical causes for spontaneous pneumothoraces in patients with a
low thoracic index whose chests were transversely wider at the apex and flatter at the base. Me-
chanical stress was found to be 20 times higher in these patients during maximal breathing ma-
neuvers such as coughing or strain activities [18]. Based on these reports and on our own
observations of our patients that pneumothoraces were associated with physical activity and
coughing after ELVR we asked: are patients less likely to develop pneumothoraces if their
post-operative care is modified to limit physical activity with bed rest (BR) and cough suppres-
sion (CS) with codeine administered as needed, when added to standard post-implantation
management?
Methods
Patients
Between October 2010 and March 2014, in total, 72 consecutive COPD patients with severe ho-
mogeneous or heterogeneous emphysema and negative collateral ventilation (CV) status as-
sessed by the Chartis console (Pulmonx Inc., USA) were treated with endobronchial valves
(Pulmonx Inc., USA) at the Charité Hospital in Berlin, Germany.
The eligibility criteria for ELVR treatment with valves included either male or female pa-
tients over 18 years of age diagnosed with severe lung emphysema GOLD stage III or IV and a
nonsmoker status for at least six months as verified by several tests of carboxyyhemoglobin
(HbCO) levels below 2.0%. The exclusion criteria were a forced expiratory volume in one
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second (FEV1) either below 15% of the predicted value (pred.) or more than 50% pred., a resid-
ual volume (RV) below 150% pred., a total lung capacity (TLC) below 100%, the presence of
interlobar collateral ventilation by the Chartis assessment, a body mass index (BMI) more than
35 kg/m2, pregnancy or major comorbidities such as significant pulmonary hypertension or
unstable cardiac conditions.
Study design
This study was a retrospective analysis. The study design was approved by the ethics committee
of Charité University Hospital (E-No: EA1/280/14). Prior to analysis, patient records/informa-
tion was anonymized and de-identified. Seventy two (72) consecutive patients were treated
with endobronchial valves. Thirty-two (32) patients were treated with standard medical care
(SMC) without restriction to bed rest and 40 patients followed a modified medical care (MMC)
that included 48 hours strict bed rest and, if needed, 16 mg codeine up for cough to three times
a day (TID). All SMC patients who were treated between October 2010 and September 2012
received the standard conventional postoperative management including post-interventional
antibiotic treatment (sulbactam and ampicillin or moxifloxacin for five days) and thromboem-
bolic prophylaxis, but with no restriction on BR and no cough suppression. The patients were
asked to mobilize immediately after the valve implantation in order to avoid thromboembolic
events. In the context that strain activity and coughing is reported to induce pneumothoraces
and based on our clinical observation of a high rate of strain activity and coughing related to
pneumothoraces under conventional postoperative management we decided to add BR for 48
hours to limit physical activity and, as needed, cough suppression with 16 mg Codeine up to
TID to the standard conventional postoperative management. This new postoperative manage-
ment procedure was applied to 40 patients treated between October 2012 and March 2014.
There were only two patients in the SMC-cohort whose weakened conditions limited their
taking of meal to their rooms. These two patients did not develop a pneumothorax. All compli-
cations and the development of an atelectasis during hospitalization were analyzed retrospec-
tively from patient files and chest X-rays in all 72 patients (Fig 1A). Nine out of the 72 patients
were treated twice after valve removal following pneumothorax (n = 1), severe infection
(n = 2), leakage (n = 3) or valve expectoration (n = 3). These patients were included only once
in the study and grouped exclusively with the last treatment into MMC or SMC. For example,
one patient with a pneumothorax after the first treatment was treated again in September 2012
in the left upper lobe and developed another pneumothorax after the second treatment, both
times without restriction to BR; thus, this patient was included only once in the SMC cohort.
Another example is a patient who was initially treated in the left lower lobe in July 2012 with-
out a pneumothorax but whose valves were removed because of migration and pneumonia two
months later. This patient developed a pneumothorax after the second treatment in July 2013
on the second day after treatment of the left lower lobe despite BR; thus, this patient was in-
cluded in the MMC cohort. Finally, no patient experiencing a pneumothorax was overlooked.
Five patients received narcotic medication during hospitalization comprising three patients in
the SMC-cohort who received Morphine 2% five drops per day, MST 10mg 1-0-1, Valoron N
retard 150 12mg, 0-0-1 versus two patients in the MMC-cohort who received Tilidine/Nalox-
one 100mg 1-0-1 and Palladone 8mg 1-0-0/MST 10mg 1-0-1. The clinical outcomes and com-
plications during a three month follow up were assessed in 62 out of 72 patients treated with
valves. Ten patients did not receive a follow up examination because of previous valve removal
(n = 4) or because patients refused further examinations after ELVR (n = 6).
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ELVR treatment
Before valve implantation, all patients had an outpatient visit for a physical examination, opti-
mization of COPD medication, pulmonary function and diffusion tests (Weinmann, Ger-
many), Six minute walk test (6MWT), St. George`s Respiratory Questionnaire (SGRQ) and
blood gas analysis. The SGRQ ranges from 0 to 100, a higher score indicating a lesser quality of
life. Patients also were sent to cardiologists to rule out significant pulmonary hypertension and
unstable coronary heart disease. To evaluate lung destruction and emphysema distribution, pa-
tients received CT scans in a low dose technique without contrast agent prior to valve treat-
ment. To ensure there were no differences in the number of homogeneous and heterogeneous
emphysema patients between the two cohorts, which might have caused a bias in clinical out-
comes and the probability of occurrence of pneumothorax, the emphysema score was analyzed
with the MevisPulmo3D software (Fraunhofer, Bremen, Germany). Heterogeneous emphyse-
ma was defined as emphysema differing by more than 15% between the ipsilateral upper and
lower lobes.
Collateral ventilation was assessed with the Chartis console in a bronchoscopic setting. Pa-
tients meeting the eligibility criteria were hospitalized one day prior to ELVR valve treatment
and checked if they were in stable condition. In both cohorts, endobronchial valves (Zephyr,
Pulmonx Inc.) were inserted unilaterally by the same bronchoscopist with a flexible broncho-
scope into lobar, segmental or sub segmental bronchi according to the patient`s individual
Fig 1. Study design. Seventy-two CV negative patients were treated with endobronchial valves at Charité Hospital between 2010 and 2014. In a
retrospective study design, complications and development of an atelectasis were evaluated during hospitalization in all 72 patients comprising 32 patients
with Standard Medical Care (SMC) (without restriction to bed rest) and 40 patients with Modified Medical Care (MMC) including strict 48 hour bed rest and
cough suppression. Complication rate and clinical outcomes comprising pulmonary function, 6MWT and SGRQ during a three month follow up were
assessed in 62 out of the 72 valve treated patients. CT scans at 3 months were available for 26 patients in the SMC and 29 patients in the MMC-cohort. CV:
collateral ventilation. PFT: pulmonary function test. SGRQ: St. George respiratory questionnaire, TLVR: target lobe volume reduction, 6MWT: six minute
walk test.
doi:10.1371/journal.pone.0128097.g001
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lung anatomy. The target lobe for treatment was the CV negative lobe with the highest emphy-
sema distribution and/or lung destruction. For the bronchoscopic anaesthesia, midazolam and
propofol were used. For ELVR all patients were admitted to the hospital and the hospital stay
was similar in both groups (Table 1). In all patients, chest X-rays were taken before ELVR, one
and three days after ELVR, and on the day of discharge to evaluate signs of lung volume reduc-
tion and to rule out a pneumothorax. All chest X-rays taken during hospitalization were retro-
spectively reassessed by two radiologists who were blinded to the study groups and results.
Atelectatic signs in X-rays were defined as the detection of patchy opacities, mediastinal shift
or elevation of the diaphragm. Patients were discharged in a clinically stable condition after at
least four days following ELVR. A complicated pneumothorax was defined as a patient receiv-
ing a chest tube for treatment of a pneumothorax for more than five days. An exacerbation was
Table 1. Demographic characteristics of the study population1.
Parameter SMC MMC p-value2
N 32 40
Sex (male/female) 25/7 20/20 0.01
Age (yr) 68±1 69±1 0.9
BMI (kg/m2)3 25±1 24±1 0.2
Smoking history (pack-yr) 48±5 41±3 0.6
COPD stage
GOLD III 7 10 0.8
GOLD IV 25 30 0.8
Emphysema distribution
homogeneous 11 20 0.2
heterogeneous 9 14 0.1
Valves per patient 4±0 4±0 0.8
Treatment site4
RUL 5 3 0.3
RLL 4 3 0.5
LUL 8 9 0.8
LLL 15 25 0.2
Pulmonary function test5
FEV1 24±1 27±1 0.3
RV 217±10 223±7 0.4
DLCO 30±5 23±3 0.8
FVC 55±2 59±2 0.1
6MWT6 211.3±20 217.3±18 1.0
SGRQ7 63.2±3 67.4±2 0.5
1 Data are presented as mean ± standard error or number of patients
2 Group comparisons were made with the Mann-Whitney U test and the Chi Square test
3 Body mass index
4 RUL right upper lung, RLL right lower lung, LUL left upper lung, LLL left lower lung
5 Pulmonary function testing parameters are given as percent of predicted value; FEV1—forced expiratory
volume in 1 sec, FVC—forced vital capacity, RV—residual volume, DLCO—diffusing capacity
6 Six minute walk test
7 St. George’s Respiratory Questionnaire
SMC: Standard Medical Care
MMC: Modiﬁed Medical Care
doi:10.1371/journal.pone.0128097.t001
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defined as subjective dyspnea requiring a higher dosage of corticosteroids. Pneumonia was
reported when patients had productive coughing with pus in their sputum, and who were
administered antibiotics.
Follow-up
At three months, patients received a physical examination, pulmonary function and diffusion
tests, 6MWT, SGRQ and blood gas analysis. CT scans were performed in 26 patients of SMC
group and 29 patients of the MMC cohort and analyzed with Pulmo3D to determinate the tar-
get lobe volume reduction (TLVR). A TLVR of more than 350ml was defined as a significant
volume reduction. Complications after ELVR were assessed in a questionnaire that included
exacerbations, pneumonia and other infections, hemoptysis, hospital stays, and thromboem-
bolic events, among others.
Statistics
The chi-square test and the Fisher Exact test for discrete variables were used for statistical anal-
ysis of categorical variables. The one-way analysis of variance (ANOVA) was used to compare
atelectasis scores between the two groups. The Man-Whitney-U test was used for ordinal vari-
ables. A p value<0.05 was considered statistically significant. A logistic regression analysis
with the factors study group and gender was performed in order to adjust for a possible influ-
ence of gender on the occurrence of pneumothorax. The data are displayed as mean +/- stan-
dard error. SPSS (IBM, version 20) was used for all statistical analyses.
Results
Patients
Seventy-two patients were treated with endobronchial valves, comprising 32 patients without
restriction to bed rest (SMC cohort)) and 40 patients with 48 hours strict bed rest, and if need-
ed for cough, 16 mg codeine up to TID (MMC cohort). The baseline characteristics are listed
in Table 1. Both cohorts were similar with regard to age (p = 0.9), BMI (p = 0.2), smoking his-
tory (p = 0.6), disease stage (p = 0.8), emphysema distribution (p = 0.2), number of inserted
valves (p = 0.8), treatment site (p = 0.2), pulmonary function and diffusion tests, including
FEV1 (p = 0.3), FVC (p = 0.1), RV (p = 0.4), 6MWT (p = 1.0) and SGRQ (p = 0.5). However,
there was a significant difference in the sex ratio: 25 patients (78%) of SMC but only 20 patients
(50%) of MMC were males (p = 0.01).
Complications during Hospitalization
To evaluate complications with a focus on the pneumothorax rate, patient files and chest X-
rays taken during hospitalization were assessed retrospectively. Hospitalization time was equal-
ly long in both cohorts (p = 0.1, Table 2). There were no deaths following ELVR with valves. In
total, 10 pneumothoraces occurred over both cohorts during hospitalization, all on the ipsilat-
eral side of the treated lobes and within four days after the procedure. Overall, compared to
MMC, SMC demonstrated significantly more pneumothorax occurrence (25% (n = 8) for SMC
vs 5% (n = 2) for MMC, p = 0.02, Fig 2), particularly with respect to upper lobe treatments
(p = 0.008, Table 2). SMC more often had complicated pneumothoraces characterized by
drainage therapy lasting longer than five days (p = 0.02) and more frequently developed bron-
cho pleural fistula (p = 0.04), compared to MMC. In SMC, three patients were transferred
with respiratory failure to the ICU because of pneumothoraces and one MMC patient because
of pneumonia and pleural effusion (p = 0.2). Valves were removed in four patients during
Modifying Medical Care after EBVMay Reduce Pneumothorax Incidence
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hospitalization: three SMC patients because of pneumothorax and one MMC patient because
of pleural effusion and pneumonia, defined as productive coughing with pus in the sputum
and administered antibiotic therapy. In both groups there were no significant differences in
other complications including exacerbations defined as subjective dyspnea requiring a higher
dosage of corticosteroids (p = 0.8), pneumonia (p = 0.4), pleural effusion (p = 0.8), hemoptysis
(p = 0.3) and thromboembolic events (p = n.a). Although there is a significant difference in the
sex ratio between the two cohorts (p = 0.01) and pneumothoraces occurred significantly more
frequent in the SMC-cohort (p = 0.02) there was no significant association between the sex
ratio and the occurrence of pneumothoraces in our study cohort (p = 0.7). In order to adjust
for a possible influence of gender on the occurrence of pneumothorax we performed a logistic
regression analysis with the factors study group and gender. Again, gender had no significant
effect on the occurrence of pneumothorax following ELVR (p = 0.9) whereas the SMC and
MMC factor remained significant in the regression analysis (p = 0.02).
Complications occurring between discharge after ELVR and three-
months follow-up
To examine whether MMC was associated with a higher complication rate after hospital dis-
charge, complications within three months after valve implantation were assessed in 62 out of
the 72 patients There was one death of unknown cause in a SMC patient two months after
ELVR. It is noteworthy that this patient had not developed an atelectasis after ELVR by the day
Table 2. Complications during hospitalization1.
SMC MMC p-value2
Patients 32 40
Hospital stay (days) 7±1 7±1 0.1
Death 0 0 n.a
Pneumothoraces3 8 2 0.02
After UL treatment 6 0 0.008
After LL treatment 2 2 0.4
Complicated pneumothoraces4 4 0 0.02
Bronchopleural ﬁstula 3 0 0.048
Transfer to ICU5 3 1 0.2
Chest tube 7 1 0.01
Duration chest tube (days) 7±2 3 n.a
Pleural effusion 2 3 0.8
Exacerbations 8 8 0.8
Pneumonia 1 3 0.4
Thromboembolic events 0 0 n.a
Hemoptysis 1 0 0.3
Valves removal 3 1 0.2
1 Data are presented as mean ± standard error or number of patients
2 Group comparisons were made with the Mann-Whitney U test or the Fisher`s exact test
3 UL Upper lobe LL lower lobe
4 Deﬁned as drainage >5d
5 ICU Intensive care unit
SMC: Standard Medical Care
MMC: Modiﬁed Medical Care
doi:10.1371/journal.pone.0128097.t002
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of discharge. One patient in MMC who had a pneumothorax during hospitalization developed
a second pneumothorax on the ipsilateral side of the treated lobe two months after ELVR. It
was treated again with a chest tube over seven days and a full re-expansion of the lung was
achieved. In summary, there were no significant differences between groups with respect to
complications after hospital discharge (Table 3).
Fig 2. Incidence of pneumothorax after ELVR. Pneumothoraces occurred less often in the Modified Medical Care (MMC) than in the Standard Medical
Care (SMC) cohorts.
doi:10.1371/journal.pone.0128097.g002
Table 3. Complications between discharge after ELVR and three-months follow-up1.
SMC MMC p-value2
Patients 29 33
Follow-up (months) 3.1±0.3 3.3±0.2 0.4
Death 1 0 0.3
Pneumothorax 0 1 0.3
Hospitalization 4 7 0.6
Duration hospitalization (day) 4±2 6±2 0.5
Exacerbation 16 12 0.1
Pneumonia 12 7 0.1
Thromboembolic events 0 0 n.a
Hemoptysis 3 1 0.1
Valves removal 7 8 0.9
1 Data are presented as mean ± standard error or number of patients
2 Group comparisons were made with the Mann-Whitney U test or the Fisher’s exact test
SMC: Standard Medical Care
MMC: Modiﬁed Medical Care
doi:10.1371/journal.pone.0128097.t003
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Comparison of clinical outcomes after ELVR
At hospital discharge, 81% of SMC patients and 87% of MMC patients developed radiological
signs for lung volume reduction (p = 0.8, Fig 3a). At three months follow-up, 81% of SMC pa-
tients and 79% of MMC patients had a significant target lobe volume reduction (TLVR) of
more than 350ml as assessed by CT scans (p = 0.9, Fig 3b) with a mean volume reduction of
953±134ml in the SMC-cohort and 1065±110ml in the MMC-cohort (p = 0.7, Fig 3c). SMC
and MMC also showed a similar increase of FEV1 (p = 0.7, Fig 4a, Table 4), FVC (p = 0.3; Fig
4c, Table 4) and likewise a similar decrease of RV (p = 0.3, Fig 4b, Table 4). Similar improve-
ments in 6MWT (p = 0.5, Fig 4c, table 4) and SGRQ (p = 0.1, Fig 4d, table 4) were recorded.
Discussion
The major complication directly related to valve implantation is pneumothoraces that could
have serious sequelae if not treated promptly [11]. Out of 72 patients, 10 pneumothoraces oc-
curred within the first four days after valve implantation, all on the ipsilateral side of treatment.
We recorded a strikingly lower rate of pneumothoraces in MMC in comparison to SMC, and
in particular after upper lobe treatment, there were less complicated pneumothoraces and
Fig 3. Radiological changes after ELVR. A. Atelectasis at chest X-ray on the day of discharge from hospital. B. Patients with a significant TLVR of more
than 350ml at 3 months.C.Mean TLVR at 3 months. TLVR: target lobe volume reduction. SMC: Standard Medical Care. MMC: Modified Medical Care.
doi:10.1371/journal.pone.0128097.g003
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fewer bronchopleural fistulae. Other complications during hospitalization, clinical and radio-
logical outcomes during the three-month follow-up period remained similar in both groups.
It is suggested here that pneumothoraces might be related to strain activity; however, the ev-
idence available in the literature is inconclusive. Cran et al. [19] analyzed retrospectively 994
pneumothorax cases in the Royal Air Force. In 358 patients strain activity was recorded at the
time of onset. In the same study more pneumothoraces were seen during the winter, and inter-
estingly, a correlation with coughing was recorded in 120 patients. Another publication de-
scribes pneumothoraces during increased Valsalva maneuvers, as seen in playing the trumpet
or other musical instruments or blowing up balloons [16]. Interestingly, a recent paper evaluat-
ed the biomechanical forces during breathing and coughing and calculated a 20 times increased
mechanical stress for spontaneous pneumothoraces during expiration and coughing in patients
whose chests were transversely wider at the apex and flatter at the basis [18]. In contrast, Bense
et al. [17] found in 219 pneumothorax patients, retrospectively, that only 2% had moderate ex-
ertion at the time when pneumothorax occurred and no patients were exerting themselves
heavily when the symptoms began.
Fig 4. Clinical outcomes after three months compared to baseline. A. Forced expiratory volume in 1 sec (FEV1).B. Residual volume (RV). C. Forced
vital capacity (FVC),D. Six Minute walk test (6MWT). E. St. George`s Respiratory Questionnaire (SGRQ). SMC: Standard Medical Care. MMC: Modified
Medical Care.
doi:10.1371/journal.pone.0128097.g004
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The physiological cause of pneumothoraces directly related to valve implantation are hy-
pothesized to result from the rapid shifts in volume between lung lobes [11]. While the target
lobe quickly loses volume after valve implantation, the adjacent ipsilateral, untreated lobe ex-
pands to occupy the newly created space in the chest cavity. This volume shift can occur very
quickly, resulting in a parenchymal rupture of the untreated ipsilateral lobe. We have seen in
our patients some pneumothoraces associated with strain activity and coughing that we think
may be among many other important contributing risk factors for pneumothoraces after
ELVR.
In our study, we observed a high pneumothorax rate of 25% in patients with severe emphy-
sema, no collateral ventilation, no restriction to bed rest and no specific administration of
cough suppression drug following ELVR. This pneumothorax rate was higher than those re-
ported in VENT study (4.2% [3]) and Euro-VENT study (5% [2]). However, pneumothorax
criteria were different between these studies and ours: the VENT study only counted severe
pneumothoraces that lasted longer than 5 days while we counted all pneumothoraces irrespec-
tive of severity. Only about one third of VENT and Euro-VENT patients had complete fissures,
which explains that FEV1 increased an average of only by 4.3% (VENT) and 7.0% (Euro-
VENT) and the mean TLVR was only 378.4ml in the VENT patients (no data for Euro-VENT
patients). In the SMC-cohort, however, 81% of all patients had complete fissures and thus de-
veloped atelectasis during hospitalization: the FEV1 increased by +21.4±1% from baseline and
the mean TLVR was 953±134ml. The improved outcomes based on better selection criteria for
the patients also imply a higher risk for pneumothoraces. Many other groups recently reported
higher pneumothorax rates with respect to improved selection criteria: 23% Gompelmann
et al.[20], 20% Lesser et al [21]., 23% Bosc et al [22] and 17% Gieserich et al [23].
Despite the striking differences between our two groups with regard to the prevention of
pneumothoraces, these data need careful interpretation as many caveats may be present. It is
possible that the reduction of pneumothoraces is the result of other factors that were not con-
sidered in this study. Another important study limitation is its retrospective analyses design,
such that selection bias cannot be excluded and that the only data that were examined were
those recorded in the patients’ files. Another limitation is that baseline characteristics were
Table 4. Comparison of clinical outcomes at 3 months after ELVR1 vs. baseline.
SMC MMC p-value2
Patients 29 33
FEV1 (% from baseline)3 +21.4±1 +22.7±4 0.7
RV (% from baseline)4 -10.0±4 -6.6±4 0.3
FVC (% from baseline)5 +22.1±5.1 +18.7±5.7 0.4
6MWT (m from baseline)6 +23.2±14 +38.5±12 0.5
SGRQ (points from baseline)7 -4.7±4 -12.0±2 0.1
1 Data are presented as mean ± standard error or number of patients
2 Group comparisons were made with the Mann-Whitney U test or the Fisher’s exact test
3 FEV1—forced expiratory volume in 1 sec
4 RV—residual volume
5 FVC—forced vital capacity
6 Six minute walk test
7 St. George’s Respiratory Questionnaire
SMC: Standard Medical Care
MMC: Modiﬁed Medical Care
doi:10.1371/journal.pone.0128097.t004
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different with regard to sex ratio. For unknown reasons, significantly more males were treated
in the MMC group. Nevertheless, despite the higher risk of spontaneous pneumothorax for
males [24–27], our analysis shows no evidence that males are more susceptible to pneumotho-
races after ELVR than females.
Although data were available for a large number of treated patients, the total number of
pneumothoraces is in fact very small. It is important to remember that in this context small
changes in events may have large effects on the outcome of the study. Another problem is that
the confinement of patients to bed rest for 48 hours to prevent physical activity is a change of
paradigm from clinical practice that favors early mobilization. This confinement might be asso-
ciated with a greater rate of side effects, such as pneumonia or thromboembolic events. Not-
withstanding, there were no significant differences in any of the recorded complications of
exacerbation, rehospitalization, thromboembolic events and hemoptysis between the two
groups during hospitalization and follow-up. Although not statistically significant, we have
seen one late onset of pneumothorax in the MMC cohort occurring two months after ELVR
and none in the SMC cohort. Studies with a higher number of patients are needed to investigate
if bed rest avoids or in some cases delays the occurrence of pneumothoraces which may be
more dangerous as patients may develop these episodes in an outpatient setting. There was no
further evaluation of the impact of the duration of bed rest. We observed that most pneumo-
thorax events occurred within the first 48 hours after ELVR, which was our rationale for keep-
ing patients in bed for this duration. However, it might be possible that shorter or longer bed
rest times might be equally or more effective in the reduction of pneumothoraces. We do not
know whether cough suppression with codeine or bed rest was more relevant in preventing
pneumothoraces. Due to the retrospective study design we do not know if the patients in the
MMC-cohort really coughed less with the codeine-treatment than the patients in the SMC-co-
hort and thus the degree and efficiency of cough suppression remains unclear. For the treat-
ment and analyses of future patients with valves we have implemented a cough score. As the
two cohorts were not treated at the same time period, improvements in technique of the bron-
choscopist may have influenced the clinical outcomes and complication rates. Nevertheless, we
have seen similar clinical and radiological outcomes in both cohorts, thus minimizing the pos-
sibility of a training effect.
In summary, modifying post-operative care to include a 48-hour bed rest and cough sup-
pression with codeine, if needed, was found to reduce the pneumothorax rate after ELVR with
valves, while other complications and clinical outcomes remained the same in both cohorts.
These observations suggest that strain activity and other Valsalva maneuvers may be risk fac-
tors for pneumothoraces following ELVR. However, a prospective, randomized study with a
larger number of patients and similar baseline characteristics are needed to confirm the out-
comes of this study.
Acknowledgments
The authors would like to thank Melanie Krueger and Anja Baer for excellent assistance in col-
lecting the data, and IB Editorial Services for manuscript editing support.
Author Contributions
Conceived and designed the experiments: DH AP SH RHH. Performed the experiments: DH
AP FD DS RHH. Analyzed the data: DH AP FD VF NFS RHH KN. Contributed reagents/
materials/analysis tools: BTW SH NS RHH. Wrote the paper: DH DS VF SH NS RHH.
Modifying Medical Care after EBVMay Reduce Pneumothorax Incidence
PLOS ONE | DOI:10.1371/journal.pone.0128097 May 26, 2015 12 / 14
References
1. Herth FJ, Eberhardt R, Gompelmann D, Ficker JH, Wagner M, Ek L, et al. (2013) Radiological and clini-
cal outcomes of using Chartis to plan endobronchial valve treatment. Eur Respir J 41: 302–308. doi:
10.1183/09031936.00015312 PMID: 22556025
2. Herth FJ, Noppen M, Valipour A, Leroy S, Vergnon JM, Ficker JH, et al. (2012) Efficacy predictors of
lung volume reduction with Zephyr valves in a European cohort. Eur Respir J 39: 1334–1342. doi: 10.
1183/09031936.00161611 PMID: 22282552
3. Sciurba FC, Ernst A, Herth FJ, Strange C, Criner GJ, Marquette CH, et al. (2010) A randomized study
of endobronchial valves for advanced emphysema. N Engl J Med 363: 1233–1244. doi: 10.1056/
NEJMoa0900928 PMID: 20860505
4. Toma TP, Hopkinson NS, Hillier J, Hansell DM, Morgan C, Goldstraw PG, et al. (2003) Bronchoscopic
volume reduction with valve implants in patients with severe emphysema. Lancet 361: 931–933.
PMID: 12648974
5. Venuta F, de Giacomo T, Rendina EA, Ciccone AM, Diso D, Perrone A, et al. (2005) Bronchoscopic
lung-volume reduction with one-way valves in patients with heterogenous emphysema. Ann Thorac
Surg 79: 411–416; discussion 416–417. PMID: 15680805
6. Wan IY, Toma TP, Geddes DM, Snell G, Williams T, Venuta F, et al. (2006) Bronchoscopic lung volume
reduction for end-stage emphysema: report on the first 98 patients. Chest 129: 518–526. PMID:
16537847
7. Herzog D, Döllinger F, Pöllinger A, Temmesfeld-Wollbrück B, Suttorp B, Hübner RH (2014) Interven-
tional bronchological therapy. A critical evaluation. Pneumologe 11:135–143.
8. Tidwell SL, Westfall E, Dransfield MT (2012) Lung volume reduction for advanced emphysema: surgi-
cal and bronchoscopic approaches. South Med J. 105(1):56–61. doi: 10.1097/SMJ.
0b013e31823c5c49 Review. PMID: 22189668
9. Criner GJ, Mamary AJ (2010) Lung Volume Reduction Surgery and Lung Volume Reduction in Ad-
vanced Emphysema: Who andWhy? Semin Respir Crit Care Med 31(03):348–364. doi: 10.1055/s-
0030-1254075
10. Gompelmann D, Herth FJ, Slebos DJ, Valipour A, Ernst A, Criner GJ, et al. (2014) Pneumothorax fol-
lowing Endobronchial Valve Therapy and Its Impact on Clinical Outcomes in Severe Emphysema. Res-
piration 87(6): 485–491. doi: 10.1159/000360641 PMID: 24800814
11. Valipour A, Slebos DJ, de Oliveira HG, Eberhardt R, Freitag L, Criner GJ, et al. (2014) Expert state-
ment: pneumothorax associated with endoscopic valve therapy for emphysema—potential mecha-
nisms, treatment algorithm, and case examples. Respiration 87: 513–521. doi: 10.1159/000360642
PMID: 24777292
12. Hoshino A, Imai K, Ohshima Y, Yasutomi M, Kasai M, Terai M, et al. (2014) Pneumothorax in patients
with severe combined immunodeficiency. Pediatr Int. Mar doi: 10.10.1111/ped.12325
13. Gompelmann D, Eberhardt R, Michaud G, Ernst A, Herth FJ (2010) Predicting atelectasis by assess-
ment of collateral ventilation prior to endobronchial lung volume reduction: a feasibility study. Respira-
tion 80: 419–425. doi: 10.1159/000319441 PMID: 20664194
14. Higuchi T, Reed A, Oto T, Holsworth L, Ellis S, Bailey MJ, et al. (2006) Relation of interlobar collaterals
to radiological heterogeneity in severe emphysema. Thorax 61: 409–413. PMID: 16467071
15. Shah PL, Herth FJ (2014) Current status of bronchoscopic lung volume reduction with endobronchial
valves. Thorax 69: 280–286. doi: 10.1136/thoraxjnl-2013-203743 PMID: 24008689
16. Dejene S, Ahmed F, Jack K, Anthony A (2013) Pneumothorax, music and balloons: A case series. Ann
Thorac Med 8: 176–178. doi: 10.4103/1817-1737.114283 PMID: 23922614
17. Bense L, Wiman LG, Hedenstierna G (1987) Onset of symptoms in spontaneous pneumothorax: corre-
lations to physical activity. Eur J Respir Dis 71: 181–186. PMID: 3678419
18. Casha AR, Manché A, Gatt R, WolakW, Dudek K, Gauci M, et al. (2014) Is there a biomechanical
cause for spontaneous pneumothorax? Eur J Cardiothorac Surg. 45(6):1011–6. doi: 10.1093/ejcts/
ezt659 PMID: 24644314
19. Cran IR, Rumball CA (1967) Survey of spontaneous pneumothoraces in the Royal Air Force. Thorax
22: 462–465. PMID: 6050294
20. Gompelmann D, Eberhardt R, Herth F (2014). Endoscopic volume reduction in COPD- a critical review.
Dtsch Arztebl Int. 111(49):827–833. doi: 10.3238/arztebl.2014.0827 PMID: 25556601
21. Lepper PM, Ballek D, Trudzinski F, Lensch C, Rentsch K, Langer F, et al. (2014) Endoscopic Lung Vol-
ume Reduction Using Endobronchial Valves In Patients With Very Low FEV1. Am J Respir Crit Care
Med 189:A3052.
Modifying Medical Care after EBVMay Reduce Pneumothorax Incidence
PLOS ONE | DOI:10.1371/journal.pone.0128097 May 26, 2015 13 / 14
22. Bosc C, Jankowski A, Briault A, Roth H, Reymond E, Arbib F, et al. (2014) Long-term outcomes in 35
patients with emphysema after endoscopic lung volume reduction (ELVR) with valves. Eur Respir J 44:
Suppl 58 P3734
23. GieserichW, Kraft M, Reichenberger F, Weber N, Behr J (2014) Pneumothorax in treatment of severe
emphysema with endobronchial valves. Eur Respir J 9:44. Available: http://erj.ersjournals.com/
content/44/Suppl_58/P3703, accessed 01.03.2015
24. Bense L (1992) Spontaneous pneumothorax. Chest 101: 891–892. PMID: 1555456
25. Sahn SA, Heffner JE (2000) Spontaneous pneumothorax. N Engl J Med 342: 868–874. PMID:
10727592
26. Bellemare F, Jeanneret A, Couture J (2003) Sex differences in thoracic dimensions and configuration.
Am J Respir Crit Care Med 168: 305–312. PMID: 12773331
27. Dransfield MT, Washko GR, Foreman MG, Estepar RS, Reilly J, Bailey WC. Gender differences in the
severity of CT emphysema in COPD. Chest. 2007; 132(2):464–470. doi: 10.1378/chest.07-0863 PMID:
17573503.
Modifying Medical Care after EBVMay Reduce Pneumothorax Incidence
PLOS ONE | DOI:10.1371/journal.pone.0128097 May 26, 2015 14 / 14
